Europe Omics-based Clinical Trials Market Size & Outlook

The omics-based clinical trials market in Europe is expected to reach a projected revenue of US$ 14,266.7 million by 2030. A compound annual growth rate of 8.6% is expected of Europe omics-based clinical trials market from 2025 to 2030.
Revenue, 2024 (US$M)
$8,697.2
Forecast, 2030 (US$M)
$14,266.7
CAGR, 2025 - 2030
8.6%
Report Coverage
Europe

Europe omics-based clinical trials market, 2018-2030 (US$M)

Europe omics-based clinical trials market, 2018-2030 (US$M)

Europe omics-based clinical trials market highlights

  • The Europe omics-based clinical trials market generated a revenue of USD 8,697.2 million in 2024.
  • The market is expected to grow at a CAGR of 8.6% from 2025 to 2030.
  • In terms of segment, phase iii was the largest revenue generating phase in 2024.
  • Phase I is the most lucrative phase segment registering the fastest growth during the forecast period.
  • Country-wise, Germany is expected to register the highest CAGR from 2025 to 2030.

Europe data book summary

Market revenue in 2024USD 8,697.2 million
Market revenue in 2030USD 14,266.7 million
Growth rate8.6% (CAGR from 2025 to 2030)
Largest segmentPhase iii
Fastest growing segmentPhase I
Historical data covered2018 - 2023
Base year for estimation2024
Forecast period covered2025 - 2030
Quantitative unitsRevenue in USD million
Market segmentationPhase I, Phase II, Phase III, Phase IV
Key market players worldwidePAREXEL, Pharmaceutical Product Development, Charles River Laboratories International Inc, Icon PLC, SGS AG, Eli Lilly and Co, Pfizer Inc, Novo Nordisk A/S ADR, Labcorp Drug Development, Rebus Biosystems

Other key industry trends

  • In terms of revenue, Europe region accounted for 26.6% of the global omics-based clinical trials market in 2024.
  • Globally, North America is projected to lead the regional market in terms of revenue in 2030.
  • Asia Pacific is the fastest growing regional market and is projected to reach USD 11,970.7 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Omics-Based Clinical Trials Market Companies

Name Profile # Employees HQ Website

Europe omics-based clinical trials market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to omics-based clinical trials market will help companies and investors design strategic landscapes.


Phase iii was the largest segment with a revenue share of 59.6% in 2024. Horizon Databook has segmented the Europe omics-based clinical trials market based on phase i, phase ii, phase iii, phase iv covering the revenue growth of each sub-segment from 2018 to 2030.


Reasons to subscribe to Europe omics-based clinical trials market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Europe omics-based clinical trials market databook

  • Our clientele includes a mix of omics-based clinical trials market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of continent-level data and insights on the Europe omics-based clinical trials market, including forecasts for subscribers. This continent databook contains high-level insights into Europe omics-based clinical trials market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Europe omics-based clinical trials market size, by country, 2018-2030 (US$M)

Europe Omics-Based Clinical Trials Market Share, 2024 & 2030 (US$M)

Europe omics-based clinical trials market size, by country, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more